On Sept 7, 2021 FN stopped covering OMER. We have discovered other biotechs with smaller market caps since publishing this page. We believe those companies present better risk-reward opportunities and will focus on those.
FN Summary: Omeros has 2 breakthrough therapy designations for their lead asset (Narsoplimab). Narso is currently awaiting PDUFA for HSCT-TMA, which should occur on Oct 17, 2021. Narso for IgAN (very large market) is currently in a P3 trial, but not expecting results until 2023. Company has a history of taking a long time to complete clinical trials. Company receives cash from OMIDRIA sales and has good cash reserves.
Table of Contents
This company hits all the right spots!
High Institutional Ownership
Outstanding P2 & P3 Trial (for HSCT-TMA)
Several Drugs in Clinical Trials
Good Cash Reserves
PDUFA for Narsoplimab on Oct 17, 2021
Countdown Timer 👇
Next Omeros Presentation
Cash on Hand
Est Cash End of Aug 2021
will not need to raise cash before Oct 17, 2021 PDUFA
Products & Sales Potential
Omeros Market Cap: ~ $981M as of Aug 30, 2021
Yes, we get it. This is the boring part of the page. But, it is also the most important. Read this: Importance of Management
- Founded the company and has served as our president, chief executive officer, and chairman of the board of directors since June 1994. Prior to founding Omeros, Dr Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Company Act of 1940. Dr Demopulos received his MD from the Stanford University School of Medicine and his BS from Stanford University.
- George A. Gaitanaris, MD, PhD, joined Omeros as our vice president, science in August 2006 and has served as our chief scientific officer since January 2012. From August 2003 to our acquisition of nura, Inc. in August 2006, Dr Gaitanaris served as the chief scientific officer of nura, a company that he co-founded and that developed treatments for central nervous system disorders.
- From 2000 to 2003, he served as president and chief scientific officer of Primal, Inc., a biotechnology company that was acquired by nura in 2003. Prior to co-founding Primal, he served as staff scientist at the National Cancer Institute.